Evidence map›Paper›PMID 24686382›Full record

ArticlePloS one2014

Molecular characterization of human T-cell lymphotropic virus type 1 full and partial genomes by Illumina massively parallel sequencing technology.

Rodrigo Pessôa, Jaqueline Tomoko Watanabe, Youko Nukui, Juliana Pereira, Jorge Casseb, Jorge Kasseb, Augusto César Penalva de Oliveira, Aluisio Cotrim Segurado, Sabri Saeed Sanabani

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. HTLV-1/2 prevalence in two Amazonian communities.Journal of virus eradication · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
    Kasseb, Jorge [corrected to Casseb, Jorge]
5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rodrigo PessôaDepartment of Virology, São Paulo Institute of Tropical Medicine, São Paulo, Brazil.
Jaqueline Tomoko WatanabeDepartment of Virology, São Paulo Institute of Tropical Medicine, São Paulo, Brazil.
Youko NukuiDepartment of Hematology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Juliana PereiraDepartment of Hematology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Jorge Casseb
Jorge KassebDepartment of Neurology, Institute of Infectology Emilio Ribas, São Paulo, Brazil.
Augusto César Penalva de OliveiraDepartment of Neurology, Institute of Infectology Emilio Ribas, São Paulo, Brazil.
Aluisio Cotrim SeguradoDepartment of Infectious Diseases, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Sabri Saeed SanabaniClinical Laboratory, Department of Pathology, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRInstituto de Infectologia Emílio Ribas · BRHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHere, we report on the partial and full-length genomic (FLG) variability of HTLV-1 sequences from 90 well-characterized subjects, including 48 HTLV-1 asymptomatic carriers (ACs), 35 HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and 7 adult T-cell leukemia/lymphoma (ATLL) patients, using an Illumina paired-end protocol.

methodsBlood samples were collected from 90 individuals, and DNA was extracted from the PBMCs to measure the proviral load and to amplify the HTLV-1 FLG from two overlapping fragments. The amplified PCR products were subjected to deep sequencing. The sequencing data were assembled, aligned, and mapped against the HTLV-1 genome with sufficient genetic resemblance and utilized for further phylogenetic analysis.

resultsA high-throughput sequencing-by-synthesis instrument was used to obtain an average of 3210- and 5200-fold coverage of the partial (n = 14) and FLG (n = 76) data from the HTLV-1 strains, respectively. The results based on the phylogenetic trees of consensus sequences from partial and FLGs revealed that 86 (95.5%) individuals were infected with the transcontinental sub-subtypes of the cosmopolitan subtype (aA) and that 4 individuals (4.5%) were infected with the Japanese sub-subtypes (aB). A comparison of the nucleotide and amino acids of the FLG between the three clinical settings yielded no correlation between the sequenced genotype and clinical outcomes. The evolutionary relationships among the HTLV sequences were inferred from nucleotide sequence, and the results are consistent with the hypothesis that there were multiple introductions of the transcontinental subtype in Brazil.

conclusionsThis study has increased the number of subtype aA full-length genomes from 8 to 81 and HTLV-1 aB from 2 to 5 sequences. The overall data confirmed that the cosmopolitan transcontinental sub-subtypes were the most prevalent in the Brazilian population. It is hoped that this valuable genomic data will add to our current understanding of the evolutionary history of this medically important virus.

Indexed as

Base SequenceCarrier StateDNA, ViralFemaleFilaggrin ProteinsGenome, ViralGenotypeHigh-Throughput Nucleotide SequencingHTLV-I InfectionsHumansHuman T-lymphotropic virus 1MaleMiddle AgedParaparesis, Tropical SpasticPhylogenyDNA, ViralFilaggrin ProteinsFLG protein, human

Identifiers

PMID24686382
PMCPMC3970957
OpenAlexW2034852475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.